Science Translational Medicine publishes research results from Oblique Therapeutics and Karolinska Institute on a new treatment of advanced cancer
The Gothenburg, Sweden based biotech company Oblique Therapeutics AB today announced that the world-leading medical journal Science Translational Medicine in its latest issue has published promising preclinical research results on a new type of molecules against advanced cancer. The results are based on a collaboration with Professor Elias Arnér's research group at Karolinska Institute in Stockholm. In the article, titled Irreversible Inhibition of Cytosolic Thioredoxin Reductase 1 as a Mechanistic Basis for Anticancer Therapy, the researchers show that tumor growth is effectively